Shahabi V - Search Results

1

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R. Hoos A, et al. Among authors: shahabi v. Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015. Semin Oncol. 2010. PMID: 21074069 Review.

2

An immune-active tumor microenvironment favors clinical response to ipilimumab.

Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V. Ji RR, et al. Among authors: shahabi v. Cancer Immunol Immunother. 2012 Jul;61(7):1019-31. doi: 10.1007/s00262-011-1172-6. Epub 2011 Dec 7. Cancer Immunol Immunother. 2012. PMID: 22146893 Free PMC article. Clinical Trial.

3

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.

Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, Panting L, Jure-Kunkel M, Ji RR. Shahabi V, et al. J Transl Med. 2013 Mar 22;11:75. doi: 10.1186/1479-5876-11-75. J Transl Med. 2013. PMID: 23521917 Free PMC article. Clinical Trial.

4

Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.

Shahabi V, Postow MA, Tuck D, Wolchok JD. Shahabi V, et al. Am J Clin Oncol. 2015 Feb;38(1):90-7. doi: 10.1097/COC.0b013e3182868ec8. Am J Clin Oncol. 2015. PMID: 25616204 Review.

5

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab.

Shahabi V, Whitney G, Hamid O, Schmidt H, Chasalow SD, Alaparthy S, Jackson JR. Shahabi V, et al. Cancer Immunol Immunother. 2012 May;61(5):733-7. doi: 10.1007/s00262-012-1227-3. Epub 2012 Mar 1. Cancer Immunol Immunother. 2012. PMID: 22382362 Free PMC article. Clinical Trial.

6

Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy.

Wood LM, Pan ZK, Shahabi V, Paterson Y. Wood LM, et al. Among authors: shahabi v. Cancer Immunol Immunother. 2010 Jul;59(7):1049-1058. doi: 10.1007/s00262-010-0830-4. Epub 2010 Mar 6. Cancer Immunol Immunother. 2010. PMID: 20213121 Free PMC article.

7

Development of a Listeria monocytogenes based vaccine against prostate cancer.

Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P. Shahabi V, et al. Cancer Immunol Immunother. 2008 Sep;57(9):1301-13. doi: 10.1007/s00262-008-0463-z. Epub 2008 Feb 14. Cancer Immunol Immunother. 2008. PMID: 18273616 Free PMC article.

8

Listeria monocytogenes-derived listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic ability.

Wallecha A, Wood L, Pan ZK, Maciag PC, Shahabi V, Paterson Y. Wallecha A, et al. Among authors: shahabi v. Clin Vaccine Immunol. 2013 Jan;20(1):77-84. doi: 10.1128/CVI.00488-12. Epub 2012 Nov 7. Clin Vaccine Immunol. 2013. PMID: 23136118 Free PMC article.

9

Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.

Shahabi V, Seavey MM, Maciag PC, Rivera S, Wallecha A. Shahabi V, et al. Cancer Gene Ther. 2011 Jan;18(1):53-62. doi: 10.1038/cgt.2010.48. Epub 2010 Aug 20. Cancer Gene Ther. 2011. PMID: 20725099

10

Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.

Wallecha A, Maciag PC, Rivera S, Paterson Y, Shahabi V. Wallecha A, et al. Among authors: shahabi v. Clin Vaccine Immunol. 2009 Jan;16(1):96-103. doi: 10.1128/CVI.00274-08. Epub 2008 Nov 19. Clin Vaccine Immunol. 2009. PMID: 19020110 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

27 results

Search Page